Abstract
Prostate cancer is a significant public health problem around the world. Once a patient has disease that is no longer addressable by local means, the cancer is considered incurable. Therapeutic goals at this point include not only extension of survival but also alteration of the natural history which may otherwise lead to significant pain and morbidity from the disease process- all related to metastases. While effective systemic therapies do currently exist, their roles are considered limited for many patients. Given the overwhelming incidence and annual mortality figures related to prostate cancer, there continues to be an urgent need for therapeutic advances. Protein kinases have emerged as “druggable” therapeutic targets as they control a multitude of basic cellular activities, including growth, survival, proliferation, differentiation and apoptosis. Several of these kinases have oncogenic properties as in the setting of malignancy they may be overactive and/or dysregulated leading to the excessive proliferation and motility typical of cancer cells. Small molecule inhibitors have shown efficacy in several tumor models and are actively being studied in prostate cancer. This review summarizes historical and contemporary studies evaluating kinase inhibitors in the treatment of prostate cancer.
Anti-Cancer Agents in Medicinal Chemistry
Title: Kinase Inhibitors in Prostate Cancer
Volume: 9 Issue: 10
Author(s): Suwicha Limvorasak and Edwin M. Posadas
Affiliation:
Abstract: Prostate cancer is a significant public health problem around the world. Once a patient has disease that is no longer addressable by local means, the cancer is considered incurable. Therapeutic goals at this point include not only extension of survival but also alteration of the natural history which may otherwise lead to significant pain and morbidity from the disease process- all related to metastases. While effective systemic therapies do currently exist, their roles are considered limited for many patients. Given the overwhelming incidence and annual mortality figures related to prostate cancer, there continues to be an urgent need for therapeutic advances. Protein kinases have emerged as “druggable” therapeutic targets as they control a multitude of basic cellular activities, including growth, survival, proliferation, differentiation and apoptosis. Several of these kinases have oncogenic properties as in the setting of malignancy they may be overactive and/or dysregulated leading to the excessive proliferation and motility typical of cancer cells. Small molecule inhibitors have shown efficacy in several tumor models and are actively being studied in prostate cancer. This review summarizes historical and contemporary studies evaluating kinase inhibitors in the treatment of prostate cancer.
Export Options
About this article
Cite this article as:
Limvorasak Suwicha and Posadas M. Edwin, Kinase Inhibitors in Prostate Cancer, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (10) . https://dx.doi.org/10.2174/187152009789735080
DOI https://dx.doi.org/10.2174/187152009789735080 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Preclinical Studies of PROTACs in Hematological Malignancies
Cardiovascular & Hematological Disorders-Drug Targets DNA Methyltransferase-1 Inhibitors as Epigenetic Therapy for Cancer
Current Cancer Drug Targets Analysis of Differential Gene Expression Based on Bayesian Estimation of Variance
Current Bioinformatics Antisense Therapy for Cardiovascular Diseases
Current Pharmaceutical Design Novel Mitochondria-targeted Drugs for Cancer Therapy
Mini-Reviews in Medicinal Chemistry Cancer Microbiome; Opportunities and Challenges
Endocrine, Metabolic & Immune Disorders - Drug Targets Cytokine Antibody Arrays in Biomarker Discovery and Validation
Current Proteomics New Insights of CTLA-4 into Its Biological Function in Breast Cancer
Current Cancer Drug Targets Anticancer Mammalian Target of Rapamycin (mTOR) Signaling Pathway Inhibitors: Current Status, Challenges and Future Prospects in Management of Epilepsy
CNS & Neurological Disorders - Drug Targets Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets Ceramide Kinase and the Ceramide-1-Phosphate/cPLA2α Interaction as a Therapeutic Target
Current Drug Targets Circulating Levels of VCAM and MMP-2 May Help Identify Patients with More Aggressive Prostate Cancer
Current Cancer Drug Targets Diabetic Cardiovascular Disease – AMP-Activated Protein Kinase (AMPK) as a Therapeutic Target
Cardiovascular & Hematological Agents in Medicinal Chemistry TNF-Related Apoptosis-Inducing Ligand (TRAIL): A Potential Candidate for Combined Treatment of Hematological Malignancies
Current Pharmaceutical Design Pleiotropic Effects of Omega-3 Fatty Acids
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Immunotoxins and Neuropeptide-Toxin Conjugates Experimental Applications
Mini-Reviews in Medicinal Chemistry Common Pathways in Health Benefit Properties of RSV in Cardiovascular Diseases, Cancers and Degenerative Pathologies
Current Pharmaceutical Biotechnology Peripheral Benzodiazepine Receptor (PBR) New Insight in Cell Proliferation and Cell Differentiation Review
Current Clinical Pharmacology Recent Advances in PET Imaging for Skeletal Surgery Applications
Recent Patents on Medical Imaging Anabolic Androgenic Steroids and Intracellular Calcium Signaling: A Mini Review on Mechanisms and Physiological Implications
Mini-Reviews in Medicinal Chemistry